Envafolimab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Single-chain variable fragment |
Target | PD-L1 |
Clinical data | |
Drug class | Antineoplastic agent |
ATC code | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII |
Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy.[1] It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours.[2] Envafolimab (KN035) has obtained the U.S. FDA's orphan drug designation for advanced biliary tract cancer.
References
- ^ "Envafolimab - Alphamab Oncology/Ascletis/3D Medicine". AdisInsight. Springer Nature Switzerland AG.
- ^ Markham A (February 2022). "Envafolimab: First Approval". Drugs. 82 (2): 235–240. doi:10.1007/s40265-022-01671-w. PMID 35122636. S2CID 246534311.
Categories:
- Articles with short description
- Short description is different from Wikidata
- Orphaned articles from November 2023
- All orphaned articles
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Cancer immunotherapy
- Monoclonal antibodies
- All stub articles
- Pharmacology stubs